12:41 AM EDT, 10/20/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) signed a nonbinding term sheet with Oracle Health and Life Sciences to use artificial intelligence to optimize clinical trials and improve patient care. The biopharmaceutical company said Tuesday that the collaboration will explore projects across oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases. The first program will focus on hypertension care and clinical research in Abu Dhabi, United Arab Emirates, in partnership with healthcare company M42. It aims to help identify patients with uncontrolled hypertension and improve clinical trial recruitment.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.